Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Alfred Sandrock
AddedFeb 15, 2024
UpdatedMay 31, 2026
Alfred Sandrock

Alfred Sandrock

Board Member, Voyager Therapeutics

Crunchbase

Alfred Sandrock's Career

Voyager Therapeutics
Voyager Therapeutics

Cambridge, MA, US

Board Member· Board
Transition Bio
Transition Bio

Cambridge, MA, US

Board Member· Board
Verge Genomics
Verge Genomics

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Alfred Sandrock's Career

Voyager Therapeutics
Voyager Therapeutics
Public$374M1252014Cambridge, MA, US
Board Member· Board

Leadership at Voyager Therapeutics

Steve PaulSteve PaulBoard Member
Phillip D. ZamorePhillip D. ZamoreBoard Member
Michael J HigginsMichael J HigginsBoard Member
Krystof BankiewiczKrystof BankiewiczCo-Founder
Guangping GaoGuangping GaoBoard Member
Mark KayMark KayCo-Founder

Similar to Voyager Therapeutics

Poseida TherapeuticsPoseida TherapeuticsSan Diego, CA, USGene Therapiesest. 2014Poseida TherapeuticsSan Diego, CA, US · est. 2014

San Diego-based Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company innovating cell and gene therapeutics.

Public · $460.5M314
Kriya TherapeuticsKriya TherapeuticsPalo Alto, CA, USGene Therapiesest. 2019Kriya TherapeuticsPalo Alto, CA, US · est. 2019

Kriya Therapeutics: Pioneering gene therapies for global health challenges in ophthalmology, neurology, and metabolism.

Series C · $600.5M194
NeurogeneNeurogeneNew York, NY, USGenetic Medicinesest. 2018NeurogeneNew York, NY, US · est. 2018

Neurogene Inc., a New York-based pharmaceutical company, specializes in developing genetic medicines for rare neurological diseases.

Public · $183.5M92
Intellia TherapeuticsIntellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598
Transition Bio
Transition Bio
Series A$50M502020Cambridge, MA, US
Board Member· Board

Leadership at Transition Bio

Samuel CohenSamuel CohenBoard Member
Kadi Liis SaarKadi Liis SaarCo-Founder
Gregory MillerGregory MillerCEO
Verge Genomics
Verge Genomics
Series B$134.1M832015San Francisco, CA, US
Board Member· Board

Leadership at Verge Genomics

Mario SaltarelliMario SaltarelliBoard Member
Emily MeltonEmily MeltonBoard Member
Gwen MelincoffGwen MelincoffBoard Member
Alice ZhangAlice ZhangFounder & CEO
Jason ChenJason ChenCo-Founder
Andrew R. AllenAndrew R. AllenBoard Member

Alfred Sandrock's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Alfred Sandrock

Alan GlowczwskiAlan GlowczwskiCo-Founder · Voyager BiomedicalAvi KorenblumAvi KorenblumFounder · Voyager LabsGeorge StoikosGeorge StoikosCo-Founder · TerranovaMatthew CostelloMatthew CostelloCo-Founder · Voyager PortalAnthony GirandAnthony GirandFounder · VoyagerMed